Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation

被引:7
作者
Norby, Faye L. [1 ]
Alonso, Alvaro [2 ]
机构
[1] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
基金
美国国家卫生研究院;
关键词
anticoagulants; apixaban; comparative effectiveness; dabigatran; edoxaban; evidence-based medicine; nonvalvular atrial fibrillation; real-world studies; rivaroxaban; warfarin; VITAMIN-K-ANTAGONIST; RANDOMIZED CLINICAL-TRIALS; DIRECT ORAL ANTICOAGULANTS; STROKE PREVENTION; REAL-WORLD; SYSTEMIC EMBOLISM; CHINESE PATIENTS; ANDEXANET ALPHA; LIVER-INJURY; WARFARIN;
D O I
10.2217/cer-2017-0025
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In this review, we summarize the effectiveness of rivaroxaban versus warfarin and the DOACs dabigatran, apixaban and edoxaban. The primary focus is on primary evidence from clinical trials, indirect comparison studies and real-world studies. While there are gaps in the literature, the evidence thus far indicates that rivaroxaban is superior to warfarin and similar to dabigatran, apixaban and edoxaban for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, although rivaroxaban may be associated with an elevated bleeding risk compared with other DOACs.
引用
收藏
页码:549 / 560
页数:12
相关论文
共 82 条
[1]   Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study [J].
Abraham, Neena S. ;
Singh, Sonal ;
Alexander, G. Caleb ;
Heien, Herbert ;
Haas, Lindsey R. ;
Crown, William ;
Shah, Nilay D. .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
[2]   Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation [J].
Alonso, Alvaro ;
MacLehose, Richard F. ;
Chen, Lin Y. ;
Bengtson, Lindsay G. S. ;
Chamberlain, Alanna M. ;
Norby, Faye L. ;
Lutsey, Pamela L. .
HEART, 2017, 103 (11) :834-839
[3]   Predicting Atrial Fibrillation and Its Complications [J].
Alonso, Alvaro ;
Norby, Faye L. .
CIRCULATION JOURNAL, 2016, 80 (05) :1061-1066
[4]  
[Anonymous], CIRCULATION J
[5]  
[Anonymous], GASTROENTEROLOGY
[6]  
[Anonymous], XAR RIV PRESCR INF
[7]   How long should dual antiplatelet therapy be applied after covered stent implantation? A case report on clinical implications of left anterior descending artery aneurysm treatment with covered stent implantation [J].
Hrycek, Eugeniusz ;
Zurek, Przemyslaw ;
Walawska-Hrycek, Anna ;
Nowakowski, Przemyslaw ;
Zurakowski, Aleksander .
KARDIOLOGIA POLSKA, 2023, 81 (11) :1155-1156
[8]   Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial) [J].
Bansilal, Sameer ;
Bloomgarden, Zachary ;
Halperin, Jonathan L. ;
Hellkamp, Anne S. ;
Lokhnygina, Yuliya ;
Patel, Manesh R. ;
Becker, Richard C. ;
Breithardt, Guenter ;
Hacke, Werner ;
Hankey, Graeme J. ;
Nessel, Christopher C. ;
Singer, Daniel E. ;
Berkowitz, Scott D. ;
Piccini, Jonathan P. ;
Mahaffey, Kenneth W. ;
Fox, Keith A. A. .
AMERICAN HEART JOURNAL, 2015, 170 (04) :675-+
[9]   Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation [J].
Bengtson, Lindsay G. S. ;
Lutsey, Pamela L. ;
Chen, Lin Y. ;
MacLehose, Richard F. ;
Alonso, Alvaro .
JOURNAL OF CARDIOLOGY, 2017, 69 (5-6) :868-876
[10]   Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice [J].
Beyer-Westendorf, Jan ;
Camm, A. John ;
Coleman, Craig I. ;
Tamayo, C. A. P. T. Sally .
THROMBOSIS AND HAEMOSTASIS, 2016, 116 :S13-S23